Aptevo Therapeutics Inc. 4
4 · Aptevo Therapeutics Inc. · Filed Mar 13, 2017
Insider Transaction Report
Form 4
Stromatt Scott C
Chief Medical Officer and SVP
Transactions
- Exercise/Conversion
Common Stock
2017-03-09+13,902→ 54,484 total - Tax Payment
Common Stock
2017-03-10$1.78/sh−6,570$11,695→ 69,072 total - Exercise/Conversion
Restricted Stock Unit
2017-03-01−16,269→ 190,672 total→ Common Stock (16,269 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-03-09−13,902→ 176,770 total→ Common Stock (13,902 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-03-10−24,836→ 151,934 total→ Common Stock (24,836 underlying) - Exercise/Conversion
Common Stock
2017-03-01+16,269→ 45,894 total - Tax Payment
Common Stock
2017-03-09$1.80/sh−3,678$6,620→ 50,806 total - Tax Payment
Common Stock
2017-03-01$2.02/sh−5,312$10,730→ 40,582 total - Exercise/Conversion
Common Stock
2017-03-10+24,836→ 75,642 total
Footnotes (4)
- [F1]Each RSU converts into the Issuer's common stock on a one-for-one basis.
- [F2]The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date.
- [F3]The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 13,902 on March 9, 2017 and 13,892 on March 9, 2018.
- [F4]The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017.